Nanobiotix SA has just presented new data from an open-label preclinical study evaluating the action of its nanoparticle-enhanced radiotherapy, NBTXR3, with the triple blockade of PD-1, LAG-3, and TIGIT on mice carrying cancerous cells. PD-1, LAG-3 and TIGIT are three checkpoint inhibitors which regulate the natural killer cells usually targeted in combination therapy in immuno-oncology.